Sun Pharma has launched generic Exelon, rivastigmine tartrate capsules in the US market. Earlier, US FDA had granted final approval for the company's ANDA to market these products. Company has 180-day marketing exclusivity

These generic rivastigmine capsules are therapeutically equivalent of Novartis Exelon capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon have annual sales of approximately USD 130 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon with a para IV certification, shares a 180-day marketing exclusivity.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson’s disease.